Qilu Pharmaceutical's Denosumab Injection (Lukexin®) Officially Launched to Benefit Patients Nationwide

On October 25, Qilu Pharmaceutical's denosumab injection (Lukexin®) was officially shipped and will soon enter the market, benefiting a large number of patients.

The arrival of Lucotin® has added a new growth driver to Qilu Pharmaceutical's biologics sector. Various relevant departments, including the Research Institute of Pharmaceutical Affairs, the Biotechnology Development Research Institute, the Biologics Company, the Sales Company, the Group Materials Management Center, and the main plant, have made advance preparations and worked together efficiently. From determining packaging design, packaging materials, and other preliminary tasks, to workshop equipment debugging and production assurance, and then to testing, release, and planning warehouse shipping matters, all processes were completed with high efficiency and quality. The first batch of products was successfully launched and shipped in the shortest possible time, striving to deliver the medicine to patients as quickly as possible.

Cold chain trucks fully loaded with denosumab injection solution slowly drove out of Qilu Pharmaceutical Biomedical Industrial Park, and will soon be transported to hospitals across China, bringing new treatment options for patients with osteoporosis.

The launch of Lucotin® has greatly met the clinical medication needs and reduced the burden on patients. Qilu Pharmaceutical always adheres to the core values of "Great doctors are sincerely devoted, family and country under heaven," insisting on making good medicines with dedication, providing patients with higher quality products and services, demonstrating the responsibility and commitment of a national pharmaceutical enterprise, and expressing our love through technology.

Editor: Baiji

Disclaimer: This article is a reprint from Yaozhi.com. The images and text are the property of the original author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.